Ieva Mirskytė, Jūratė Kasnauskienė, Alvydas Česas, Loreta Radvinskienė
With the advent of the molecular-targeted therapy, rapid progress has been made in the treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). EGFR mutations detection in tumor is important to determine an appropriate treatment of EGFR TK inhibitors. We investigated EGFR mutation status for patients with non-small cells lung carcinoma (NSCLC) patients’ tumorous cells from FFPE material in Klaipeda University Hospital, Lithuania (mutation test for the qualitative detection and identification of mutations in exons 18, 19, 20 and 21 of the EGFR gene) and T790M mutation in cfDNA (Liquid biopsy). Mutations of EGFR from FFPE were detected in 24 of the 119 patients (20%). EGFR mutations were more frequently found in women (13 of 36, 36%). cfDNA (Liquid biopsy) testing results show one of the patients had EGFR 20 exon T790M mutation detected which is resistance determining factor for the first and second generation EGFR TK Inhibitors treatment and a predicting marker for the third generation EGFR TK Inhibitors treatment.
Keyword(s): non-small-cell lung cancer (NSCLC); targeted therapies; tyrosine kinase inhibitors; EGFR mutation; cfDNA.
Full Text: PDF